Literature DB >> 2934735

Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants.

Z Steplewski, G Spira, M Blaszczyk, M D Lubeck, A Radbruch, H Illges, D Herlyn, K Rajewsky, M Scharff.   

Abstract

Three different monoclonal antibody isotypes, IgG1, IgG2b, and IgG2a, were derived by selection of isotype-switch variants from the CO-19-9 hybridoma. All three antibodies retained their binding specificities and affinities and bound to the same epitope--as defined by the anti-idiotype analysis. Availability of gamma 1, gamma 2b, and gamma 2a Ig heavy chain variants directed against the same epitope on the monosialoganglioside antigen permitted detailed analysis of their Fc fragment receptor (FcR) binding affinities, their cytolytic activities (antibody-dependent, macrophage-mediated cytotoxicity) in vitro, and their tumoricidal activities in vivo. Analysis of the binding of three isotypes to the human FcR expressed by U937 cells induced by gamma interferon has shown that only IgG2a proteins bound to high-affinity FcR, but not IgG1 or IgG2b variants. Although all three isotypes were active in the antibody-dependent, macrophage-mediated cytotoxicity assay with murine thioglycolate-elicited macrophages, the IgG2a gave the highest percentage of lysis; similar results were obtained in the same assay with human monocytes as effector cells. In the nude mice experiment, only the IgG2a variant inhibited growth of human colorectal carcinoma, while IgG1 and IgG2b were ineffective. Thus, selection of isotype-switch variants resulted in the conversion of monoclonal antibody from noncytolytic to cytolytic with possible immunotherapeutic application.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934735      PMCID: PMC391494          DOI: 10.1073/pnas.82.24.8653

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Isolation of variants of mouse myeloma X63 that express changed immunoglobulin class.

Authors:  A Radbruch; B Liesegang; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

2.  Colorectal carcinoma antigens detected by hybridoma antibodies.

Authors:  H Koprowski; Z Steplewski; K Mitchell; M Herlyn; D Herlyn; P Fuhrer
Journal:  Somatic Cell Genet       Date:  1979-11

3.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

4.  Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells.

Authors:  Z Steplewski; T H Chang; M Herlyn; H Koprowski
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

5.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

6.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

7.  A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

Authors:  J L Magnani; B Nilsson; M Brockhaus; D Zopf; Z Steplewski; H Koprowski; V Ginsburg
Journal:  J Biol Chem       Date:  1982-12-10       Impact factor: 5.157

8.  Mass spectrometry of a human tumor glycolipid antigen being defined by mouse monoclonal antibody NS-19-9.

Authors:  K E Falk; K A Karlsson; G Larson; J Thurin; M Blaszczyk; Z Steplewski; H Koprowski
Journal:  Biochem Biophys Res Commun       Date:  1983-01-27       Impact factor: 3.575

9.  A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma.

Authors:  J L Magnani; M Brockhaus; D F Smith; V Ginsburg; M Blaszczyk; K F Mitchell; Z Steplewski; H Koprowski
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

10.  Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells.

Authors:  D Herlyn; M Herlyn; Z Steplewski; H Koprowski
Journal:  Cell Immunol       Date:  1985-04-15       Impact factor: 4.868

View more
  13 in total

1.  Enhancing monoclonal antibodies and hybridoma cell lines.

Authors:  S S Seaver
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

2.  Flow cytometric analysis of sialyl Lewis A antigen on human cancer cells by using F(ab')2μ fragments prepared from a mouse IgM monoclonal antibody.

Authors:  K Morimoto; K Inouye
Journal:  Cytotechnology       Date:  1997-09       Impact factor: 2.058

3.  Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

Authors:  C J Honsik; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

4.  Development of an anti-guinea pig CD4 monoclonal antibody for depletion of CD4+ T cells in vivo.

Authors:  Brianne N Banasik; Clarice L Perry; Celeste A Keith; Nigel Bourne; Hubert Schäfer; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2019-08-14       Impact factor: 2.303

5.  Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.

Authors:  J E Sanford; D M Lupan; A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

6.  T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.

Authors:  C M Henningsson; S Selvaraj; G D MacLean; M R Suresh; A A Noujaim; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.

Authors:  A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

Authors:  M Naramura; S D Gillies; J Mendelsohn; R A Reisfeld; B M Mueller
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

9.  Human parathyroid antigen: characterization and localization with monoclonal antibodies.

Authors:  W G Cance; S A Wells; W G Dilley; M J Welch; F L Otsuka; J M Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

10.  The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.

Authors:  C F Scott; V S Goldmacher; J M Lambert; R V Chari; S Bolender; M N Gauthier; W A Blättler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.